Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsGlobeNewsWire • 10/23/24
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and TherapeuticsGlobeNewsWire • 10/10/24
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical DevelopmentGlobeNewsWire • 10/09/24
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/09/24
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/09/24
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/12/24
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/12/24
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024GlobeNewsWire • 06/21/24
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051GlobeNewsWire • 06/17/24
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical TrialGlobeNewsWire • 05/28/24
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/14/24
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/13/24
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024GlobeNewsWire • 04/10/24
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/26/24
Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 millionGlobeNewsWire • 03/14/24
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 MillionGlobeNewsWire • 03/11/24
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing CancersGlobeNewsWire • 03/11/24
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024GlobeNewsWire • 03/05/24
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase InhibitorGlobeNewsWire • 02/06/24
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024GlobeNewsWire • 01/04/24
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/09/23
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality PortfolioGlobeNewsWire • 10/16/23